Global Blood Therapeutics

General Information

We are a biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. We are developing our initial product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease, or SCD, and are currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind clinical trial that we characterize as a Phase 1/2 clinical trial. SCD is a disease marked by severe pain “crises,” recurrent hospitalizations, multi-organ damage, and early mortality. GBT440 targets the underlying mechanism of red blood cell sickling, which we believe may provide the potential to treat SCD rather than only its associated symptoms. In addition to GBT440 for the treatment of SCD, we are leveraging our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema, or HAE. We own rights to our product candidate portfolio in the United States, Europe and other major markets.

Employees: 47
Founded: 2011
Contact Information
Address 400 East Jamie Court, Suite 101, South San Francisco, CA 94080
Phone Number (650) 741-7700
Web Address
View Prospectus: Global Blood Therapeutics
Financial Information
Market Cap $556.2mil
Revenues $0.0 mil (last 12 months)
Net Income $-26.7 mil (last 12 months)
IPO Profile
Symbol GBT
Exchange NASDAQ
Shares (millions): 6.0
Price range $20.00 - $20.00
Est. $ Volume $120.0 mil
Manager / Joint Managers Morgan Stanley/ Goldman Sachs
CO-Managers Cowen and Company/ Wedbush PacGrow
Expected To Trade: 8/12/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change